Helicobacter pylori therapy: what is coming?

Bibliography

• ZULLO A, HASSAN C, CAMPO SM, MORINI S: Evolving therapy for H. pylori infection. Expert Opin. Ther. Patents (2004) 14:1453-1464.
   Web of Science ®Google Scholar
• MEGRAUD F: H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut (2004) 53:1374-1384.
   PubMed Web of Science ®Google Scholar
• EHPSG: Current European concepts in the management of H. pylori infection. The Maastricht Consensus Report. Gut (1997) 41:8-13.
   PubMedGoogle Scholar
• MALFERTHEINER P, MÉGRAUD F, MORAIN CO et al.: Current concepts in the management of H. pylori infection. The Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. (2002) 16:167-180.
   PubMed Web of Science ®Google Scholar
• GENÈ E, CALVET X, AZAGRA R, GISBERT JP: Triple vs. quadruple therapy for treating H. pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. (2003) 17:1137-1143.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, BELSON G, ABUDAYYEDI S, OSATO MS, DORE MP, EL ZIMAITY HM: Twice daily (midday and evening) quadruple therapy for H. pylori infection in the US. Dig. Liver Dis. (2004) 36:384-387.
   PubMedGoogle Scholar
• ZULLO A, HASSAN C, MORINI S: Quadruple therapy as a first-line H. pylori treatment: past or future? Dig. Liver Dis. (2004) 36:377-379.
   PubMedGoogle Scholar
• FISCHBACH LA, VAN ZANTEN SV, DICKASON J: Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-H. pylori quadruple therapies. Aliment. Pharmacol. Ther. (2004) 20:1071-1082.
   PubMed Web of Science ®Google Scholar
• NEVILLE PM, EVERETT S, LANGWORTHY H et al.: The optimal antibiotic combination in a 5-day H. pylori eradication regimen. Aliment. Pharmacol. Ther. (1999) 13:497-501.
   PubMedGoogle Scholar
• BORODY TJ, ASHMAN O: Lactoferrin: milking ulcers? Dig. Liver Dis. (2003) 35:691-693.
   PubMedGoogle Scholar
• DI MARIO F, ARAGONA G, DAL BO N et al.: Use of bovine lactoferrin for H. pylori eradication. Dig. Liver Dis. (2003) 35:706-710.
   PubMedGoogle Scholar
• DI MARIO F, ARAGONA G, DAL BO N et al.: Bovine lactoferrin for H. pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther. (2006) 23:1235-1240.
   PubMedGoogle Scholar
• GUTTNER Y, WINDSOR HM, VIIALA CH, MARSHALL BJ: Human recombinant lactoferrin is ineffective in the treatment of human H. pylori infection. Aliment. Pharmacol. Ther. (2003) 17:125-129.
   PubMed Web of Science ®Google Scholar
• ZULLO A, DE FRANCESCO V, SCACCIANOCE G et al.: Quadruple therapy with lactoferrin for H. pylori eradication: a randomised, multicentre study. Dig. Liver Dis. (2005) 37:496-500.
   PubMedGoogle Scholar
• ZULLO A, DE FRANCESCO V, SCACCIANOCE G et al.: Comparison between quadruple therapy with lactoferrin and low-dose levofloxacin-based triple therapy for H. pylori eradication: preliminary results of a multicenter study. Dig. Liver Dis. (2006) 38:S66-S67 (abstract).
   Google Scholar
• ZULLO A, RINALDI V, WINN S et al.: A new highly effective short-term therapy schedule for H. pylori eradication. Aliment. Pharmacol. Ther. (2000) 14:715-718.
   PubMed Web of Science ®Google Scholar
• ZULLO A, VAIRA D, VAKIL N et al.: High eradication rates of H. pylori with a new sequential treatment. Aliment. Pharmacol. Ther. (2003) 17:719-726.
   PubMed Web of Science ®Google Scholar
• SCACCIANOCE G, HASSAN C, PANARESE A, PIGLIONICA D, MORINI S, ZULLO A: H. pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can. J. Gastroenterol. (2006) 20:113-117.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCO V, ZULLO A, HASSAN C et al.: The prolongation of triple therapy for H. pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig. Liver Dis. (2004) 36:322-326.
   PubMedGoogle Scholar
• DE FRANCESCO V, MARGIOTTA M, ZULLO A et al.: Clarithromycin-resistant genotypes and eradication of H. pylori. Ann. Int. Med. (2006) 144:94-100.
   PubMed Web of Science ®Google Scholar
• CAMMAROTA G, CIANCI R, CANNIZZARO O et al.: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for H. pylori infection. Aliment. Pharmacol. Ther. (2000) 14:1339-1343.
   PubMed Web of Science ®Google Scholar
• CAMMAROTA G, MARTINO A, PIROZZI G et al.: High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for H. pylori infection. Aliment. Pharmacol. Ther. (2004) 19:789-795.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO Y, MIKI I, AOYAMAB N et al.: Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig. Liver Dis. (2005) 37:821-825.
   PubMedGoogle Scholar
• GATTA L, ZULLO A, PERNA F et al.: A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment. Pharmacol. Ther. (2005) 22:45-49.
   PubMed Web of Science ®Google Scholar
• ZULLO A, DE FRANCESCO V, HASSAN C, PANELLA C, MORINI S, IERARDI E: Second-line treatment for H. pylori eradication after sequential therapy failure: a pilot study. Therapy (2006) 3:251-254.
   Google Scholar
• GISBERT JP, MORENA F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after H. pylori treatment failure. Aliment. Pharmacol. Ther. (2006) 23:35-44.
   PubMed Web of Science ®Google Scholar
• DI CARO S, OJETTI V, ZOCCO MA et al.: Mono, dual and triple moxifloxacin-based therapies for H. pylori eradication. Aliment. Pharmacol. Ther. (2002) 16:527-532.
   PubMedGoogle Scholar
• NISTA EC, CANDELLI M, ZOCCO MA et al.: Moxifloxacin-based strategies for first-line treatment of H. pylori infection. Aliment. Pharmacol. Ther. (2005) 21:1241-1247.
   PubMed Web of Science ®Google Scholar
• CHEON JH, KIM N, LEE DH et al.: Efficacy of moxifloxacin-based triple therapy as second-line treatment for H. pylori infection. Helicobacter (2006) 11:46-51.
   PubMed Web of Science ®Google Scholar
• CANDUCCI F, CREMONINI F, ARMUZZI A et al.: Probiotics and H. pylori eradication. Dig. Liver Dis. (2002) 34:S81- S83.
   PubMedGoogle Scholar
• GOTTELAND M, BRUNSER O, CRUCHET S: Systematic review: are probiotics useful in controlling gastric colonization by H. pylori? Aliment. Pharmacol. Ther. (2006) 23:1077-1086.
   PubMed Web of Science ®Google Scholar
• SAGGIORO A, CAROLI M, PASINI M et al.: H. pylori eradication with lactobacillus reuteri: a double-blind, placebo-controlled study. Dig. Liver Dis. (2002) 37:S88 (abstract).
   Google Scholar
• SHIMBO I, YAMAGUCHI T, ODAKA T et al.: Effect of Clostridium butyricum on fecal flora in H. pylori eradication therapy. World J. Gastroenterol. (2005) 11:7520-7524.
   PubMed Web of Science ®Google Scholar
• OHNO T, KITA M, YAMAOKA Y et al.: Antimicrobial activity of essential oils against H. pylori. Helicobacter (2003) 8:207-215.
   PubMed Web of Science ®Google Scholar
• O’MAHONY R, AL-KHTHEERI H, WEERASEKERA D et al.: bacteriocidal and anti-adhesive properties of culinary and medicinal plants against H. pylori. World J. Gastroenterol. (2005) 11:7499-7507.
   PubMed Web of Science ®Google Scholar
• HARISTOY X, FAHEY JW, SCHOLTUS I, LOZNIEWSKI A: Evaluation of the antimicrobial sffects of several isothiocyanates on H. pylori. Planta Med. (2005) 71:326-330.
   Google Scholar
• HARISTOY X, ANGIOI-DUPRREZ K, DUPREZ A, LOZNIEWSKI A: Efficacy of sulforaphane in eradicating H. pylori in human gastric xenographs implanted in nude mice. Antimicrob. Agents Chemother. (2003) 47:3982-3984.
   PubMed Web of Science ®Google Scholar
• GALAN MV, KISHAN AA, SILVERMAN AL: Oral broccoli sprouts for the treatment of H. pylori infection: a preliminary report. Dig. Dis. Sci. (2004) 49:1088-1090
   Google Scholar
• ZULLO A, RINALDI V, HASSAN C et al.: H. pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Ital. J. Gastroenterol. Hepatol. (1998) 30:405-408.
   PubMedGoogle Scholar
• POPE AJ, TOSELAND CD, RUSHANT B, RICHARDSON S, MCVEY M, HILLS J: Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vivo and in vitro. Dig. Dis. Sci. (1998) 43:109-119.
   PubMed Web of Science ®Google Scholar
• KIM JI, PARK SH, KIM JK et al.: The effects of nocturnal acid breacktrhrough on H. pylori eradication. Helicobacter (2002) 7:331-336.
   PubMed Web of Science ®Google Scholar
• THOMSON AB, COHEN P, FICHEUX H: Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment. Pharmacol. Ther. (2006) 23:1179-1187.
   PubMed Web of Science ®Google Scholar
• ANNIBALE B, CAPURSO G, DELLE FAVE G: The stomach and iron deficiency anaemia: a forgotten link. Dig. Liver Dis. (2003) 35:288-295.
   PubMedGoogle Scholar
• FRANCHINI M, VENERI D: H. pylori infection and immune thrombocytopenic purpura: an update. Helicobacter (2003) 9:342-346.
   Google Scholar